Match!
William Jimenez
Mercy Medical Center (Baltimore, Maryland)
12Publications
6H-index
93Citations
Publications 12
Newest
e15123 Background: Vascular endothelial growth factor receptor 2 (VEGFR-2) is considered a prognostic factor and treatment target for metastatic colorectal and ovarian cancer. Peritoneal Carcinomatosis (PC) from appendiceal cancer is a rare malignancy, treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), for which tumor histology, completeness of cytoreduction (CC), and lymph node (LN) status are predictors of survival. We hypothesize that high VEGFR-2 ...
#1Nail AydinH-Index: 6
#2Armando SardiH-Index: 19
Last.GushchinH-Index: 1
view all 8 authors...
Diffuse malignant peritoneal mesothelioma (DMPM) is an uncommon malignancy, which can be difficult to treat. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have evolved as the treatment of choice when complete cytoreduction is to be achieved. This study reports the outcomes of CRS/HIPEC for peritoneal mesothelioma performed in a center for peritoneal surface malignancy. A retrospective analysis of a prospective database of 389 CRS/HIPEC procedures identified 23...
#1Maria F. Nunez (Mercy Medical Center (Baltimore, Maryland))H-Index: 4
#2Armando Sardi (Mercy Medical Center (Baltimore, Maryland))H-Index: 19
Last.Vadim Gushchin (Mercy Medical Center (Baltimore, Maryland))H-Index: 14
view all 9 authors...
Background CRS/HIPEC has evolved as a therapeutic option for selected patients with peritoneal surface malignancies. To achieve complete cytoreduction (CC), some patients require extensive abdominal-wall resection (AWR) and subsequent complex reconstructions, which may be associated with wound complications (WC) and delay of postoperative cancer therapy.
#1Maria F. Nunez (Mercy Medical Center (Baltimore, Maryland))H-Index: 4
#2Armando Sardi (Mercy Medical Center (Baltimore, Maryland))H-Index: 19
Last.Vadim Gushchin (Mercy Medical Center (Baltimore, Maryland))H-Index: 14
view all 9 authors...
Introduction Port-site metastases (PSMs) have been reported after laparoscopy in patients with peritoneal carcinomatosis (PC). We hypothesize that PSM is an independent negative predicting factor of survival in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
#1William Jimenez (Mercy Medical Center (Baltimore, Maryland))H-Index: 6
#2Armando Sardi (Mercy Medical Center (Baltimore, Maryland))H-Index: 19
Last.Vadim Gushchin (Mercy Medical Center (Baltimore, Maryland))H-Index: 14
view all 8 authors...
Background Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has survival benefit in the treatment of selected patients with peritoneal carcinomatosis (PC) from appendiceal cancer (AC). We evaluated factors affecting the survival of patients with PC from AC after CRS/HIPEC.
#1Armando Sardi (Mercy Medical Center (Baltimore, Maryland))H-Index: 19
#2William Jimenez (Mercy Medical Center (Baltimore, Maryland))H-Index: 6
Last.Chukwuemeka Wosu (Mercy Medical Center (Baltimore, Maryland))H-Index: 1
view all 3 authors...
Introduction: Disseminated Peritoneal Adenomucinosis (DPAM) is an infrequent presentation of appendiceal cancer. Infrequently, umbilical or inguinal hernias could be the first clinical manifestation of this condition; DPAM extension to the scrotum may be anatomically viable. Treatment with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard of treatment for DPAM. We hypothesize that these same treatment principles, consisting of CRS with hyperthermic...
#1William Jimenez (Mercy Medical Center (Baltimore, Maryland))H-Index: 6
#2Armando Sardi (Mercy Medical Center (Baltimore, Maryland))H-Index: 19
Last.Vadim Gushchin (Mercy Medical Center (Baltimore, Maryland))H-Index: 14
view all 4 authors...
Objective Peritoneal sarcomatosis from primary uterine sarcoma (US) is a rare condition. Conventional therapeutic modalities have failed to improve survival and outcomes among patients with high-grade US with extrapelvic spread. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown improved outcomes for peritoneal carcinomatosis from other epithelial primaries with similar clinical presentation. We report our experience applying this treatment in 3 patients...
#1Armando Sardi (Mercy Medical Center (Baltimore, Maryland))H-Index: 19
#2William Jimenez (Mercy Medical Center (Baltimore, Maryland))H-Index: 6
Last.Vadim Gushchin (Mercy Medical Center (Baltimore, Maryland))H-Index: 14
view all 6 authors...
Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has become an option for peritoneal carcinomatosis (PC). Frequently, these patients have failed systemic chemotherapies and surgeries, including CRS/HIPEC with traditional regimens (mitomycin-C or platinum based). An alternative agent for failed or repeated CRS/HIPEC is unknown. We hypothesize that melphalan is an alternative agent in patients with PC from aggressive primaries, including recurrences foll...
#1Armando SardiH-Index: 19
#2William JimenezH-Index: 6
Last.Chukwuemeka WosuH-Index: 1
view all 3 authors...
Introduction: Disseminated Peritoneal Adenomucinosis (DPAM) is an infrequent presentation of appendiceal cancer. Infrequently, umbilical or inguinal hernias could be the first clinical manifestation of this condition; DPAM extension to the scrotum may be anatomically viable. Treatment with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard of treatment for DPAM. We hypothesize that these same treatment principles, consisting of CRS with hyperthermic...
12